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were conducted by using MEGA 
version 4.1 (www.megasoftware.
net). The partial lppA gene nucleotide 
sequences of isolates GN407 and 
GN408 were submitted to GenBank 
under accession nos. HQ699892 and 
HQ699893, respectively.
PCR amplifi cations of the 2 joint 
fl uids and their cultures were positive 
for M. leachii. When we compared 
the complete 16S rRNA gene and 
the partial lppA gene, the 2 isolates 
from the same epizootic shared 100% 
nt identity. For 16S rRNA gene, the 
isolates shared 99.9%, 99.9%, and 
99.7% nt identities to M. leachii PG50, 
M. capricolum subsp. capricolum, 
and M. mycoides subsp. mycoides 
small colony, respectively. For partial 
lppA gene, the isolates shared 99.6%, 
95.1%, and 69.6% nt identities 
to M. leachii PG50, M. mycoides 
subsp. mycoides small colony, and 
M. capricolum subsp. capricolum, 
respectively.
Intraarticular inoculation of 
the passage cultures successfully 
reproduced the polyarthritis in calves 
1 month of age. Thus, there are notable 
similarities between our fi ndings 
and those reported in Australia (3). 
Multidisciplinary procedures, in-
cluding clinical assessment and 
comprehensive laboratory investiga-
tions of affected calves, were used 
to identify the etiologic agent. The 
results showed that the outbreak of 
the serious polyarthritis in calves was 
caused by M. leachii.
Our detection of M. leachii in 
China confi rms a wider geographic 
presence of this type of Mycoplasma 
spp. in cattle and suggests M. leachii 
is common and potentially distributed 
worldwide. Currently, the source of 
M. leachii infection and its means 
of spread have not been established. 
However, our epidemiologic and 
clinical investigations indicated clear 
evidence of seminal infection because 
all calves with arthritis were from 
dams that were fertilized by using the 
same batch of semen, and cows in the 
same herd that were fertilized by using 
a different batch of semen delivered 
healthy calves. More epidemiologic, 
molecular, and pathogenic studies are 
required to determine the relevance, 
distribution, importance, and diversity 
of M. leachii in cattle.
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To the Editor: Bartonella species 
are small, gram-negative, fastidious, 
and hemotropic emerging pathogens 
that cause various human diseases 
and circulate between a large variety 
of mammalian and arthropod vectors. 
More than 30 Bartonella species have 
been isolated from humans as well 
as from wild and domestic animals 
worldwide (1). B. clarridgeiae was 
suggested to be a minor causative 
agent of cat-scratch disease (CSD) 
in humans, however, this suggestion 
remains controversial. Usually, the 
agent of CSD is B. henselae and its 
principal reservoir is domestic cats 
(Felis catus) (1,2). The principal 
vector of these 2 species is the cat 
fl ea (Ctenocephalides felis) (3,4). 
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We report Bartonella species in fl eas 
collected from cats and dogs in Tahiti, 
French Polynesia.
In October 2009, fl eas were 
collected from 1 cat and 9 dogs in 
Papeete, capital of Tahiti Island, 
French Polynesia. Fleas collected 
were kept in 70% ethanol and sent 
to the military veterinary service in 
Marseille, France; these fl eas were 
later sent to Unité de Recherche sur 
les Maladies Infectieuses et Tropicales 
Emergentes in Marseilles. The fl eas 
were identifi ed phenotypically by 
using current taxonomic criteria. DNA 
from fl eas and negative control DNA 
from noninfected laboratory lice were 
extracted by using a QIAamp Tissue 
Kit (QIAGEN, Hilden, Germany), as 
described (3).
Flea samples were tested for 
Bartonella spp. DNA by using the 
7900 HT Fast Quantitative Real-Time 
PCR System (Applied Biosystems, 
Foster City, CA, USA) and primers 
and Taqman probes specifi c for the 
16S–23S rRNA gene intergenic 
spacer region as described (5). Fleas 
were considered positive when cycle 
threshold was <30. All positive 
fl eas at screening were confi rmed 
by using standard Bartonella PCR 
and sequencing of partial internal 
transcribed spacer gene fragments 
by using primers URBarto1 and 
URBarto2, as described (3). B. 
elizabethae DNA was used as positive 
control. DNA sequencing reagents 
were obtained with BigDye Terminator 
Cycle Sequencing Ready Reaction Kit 
(ABI PRISM; Applied Biosystems). 
The sequences were assembled in 
Sequencher 4.2 (GeneCodes 2003; 
www.genecodes.com) and were 
compared with Bartonella sequences 
available in GenBank.
Overall, 81 fl eas were collected 
from 1 cat (13 fl eas) and 9 dogs (68 
fl eas). All 81 fl eas collected were 
morphologically identifi ed as C. felis. 
Sample fl eas were collected from 
animals visiting a veterinary clinic for 
neutering or vaccinations. The overall 
rate of Bartonella-positive fl eas by 
molecular screening with real-time 
PCR was 7.4% (6/81): 6 fl eas from 
the cat (6/13) and none from a dog 
(0/68). These positive samples were 
confi rmed after intergenic spacer PCR 
amplifi cation and sequencing with 
sequences at 100% identity with B. 
clarridgeiae (GenBank accession no. 
EU589237).
B. clarridgeiae was fi rst isolated 
from the pet cat of an HIV-positive 
patient in the United States (6). 
However, B. clarridgeiae has never 
been isolated or detected by molecular 
methods in humans, and thus its 
implication as a human pathogen 
remains controversial. The presence 
of B. clarridgeiae antibodies has been 
reported in a suspected case of CSD 
and in a patient with a chest-wall 
abscess (4). However, B. clarridgeiae 
has been detected on fl eas from 
various continents, including Europe, 
Asia, North America (1), Africa; 
New Zealand, and recently from New 
Caledonia (7).
In France, several studies have 
reported the molecular detection of 
B. clarridgeiae in the blood of a cat 
or in cat fl eas (C. felis), indicating 
the potential role of fl eas as vectors 
of this organism (8,9). Prevalence of 
this bacterium in cat fl eas may vary 
and be as high as 67.9% in cat fl eas 
from France (3). Moreover, DNA of 
B. henselae and B. clarridgeiae has 
been reported from cat fl eas from New 
Zealand (10). Similarly, co-infection 
with B. clarridgeiae and B. henselae 
has been reported in domestic cats 
from Europe and Asia (1). In our 
study, all Bartonella spp.–positive 
fl eas harbored B. clarridgeiae only; 
all were obtained from cats and none 
from dogs, similar to fi ndings reported 
from New Zealand (10), although B. 
clarridgeiae has been reported from a 
fl ea on a dog in Taiwan (2).
Papeete, the capital of Tahiti, is 
located in the South Pacifi c Ocean, and 
remains one of the most visited areas by 
tourists from all over the world. There 
are many stray cats and dogs in Tahiti 
that may be infected with Bartonella 
species and thus serve as a reservoir for 
these pathogens. Our result confi rms 
the presence of B. clarridgeiae in Tahiti 
and is a warning of the presence of fl ea-
borne bartonellosis and the potential 
risk of B. clarridgeiae or other fl ea-
borne diseases for humans exposed to 
cat fl eas.
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To the Editor: Four species of 
human bocavirus (HBoV1–4) have 
been identifi ed since 2005 (1–4). 
Several reports have documented that 
HBoV1 are prevalent in respiratory 
tract samples. Although there may be 
many asymptomatic carriers, HBoV1 
has been shown to cause respiratory 
tract diseases (1,5,6). HBoV2 has 
mainly been detected in fecal samples 
and has been linked to gastroenteritis 
(3,7,8). HBoV3 and HBoV4 have 
recently also been detected in fecal 
samples (3,4), although no link to 
disease has been established for these 
2 species. 
In this study, we identifi ed 
and characterized 3 HBoV species 
(HBoV1–3) detected in respiratory 
samples. Nasopharyngeal aspirates 
were collected from 1,238 children 
(784 boys and 454 girls) with acute 
lower respiratory tract infections 
hospitalized in Beijing Children’s 
Hospital from March 2008 through 
July 2010. Patients’ ages ranged from 
1 month to 9 years (median 10.0 
months, mean 32.1 months).
Viral nucleic acid was extracted 
from nasopharyngeal aspirates by 
using the NucliSens easyMAG 
system (bioMérieux, Marcy l’Etoile, 
France). We screened for HBoV1–4 
by nested PCR with touch-down 
procedure using primers targeting 
the viral proteins (VP) 1/2 region 
(4). For HBoV-positive samples, 
we then quantifi ed viral loads by 
real-time PCR (online Technical 
A p p e n d i x , w w w. c d c . g o v / E I D /
content/17/9/110078-Techapp.pdf). 
Additional viral infections were 
identifi ed in all screened specimens as 
described (9). To avoid contamination, 
the PCR process (including master 
mixture preparation, nucleic acid 
extraction, reaction installation, and 
DNA amplifi cations) were performed 
in separate dedicated areas. Strict 
controls were used during the process 
of nucleic acid extraction and PCR 
analyses to monitor contamination. 
All PCR products were verifi ed by 
sequence analysis.
We found 141 positive samples 
for HBoVs (11.4%) from patients 
ranging in age from 1 to 132 months 
(median 12.0 months, mean 19.8 
months) (GenBank accession 
nos. HQ871520–HQ871650 and 
HQ871664–HQ871673). Among these 
samples, 131 (10.6%; patient ages 
1–132 months, median 12 months, 
mean 19 months) were positive for 
HBoV1, 5 (0.4%; patients 1–113 
months of age, median 7.2 months, 
mean 29.2 months) for HBoV2, and 5 
(0.4%; 1–108 months of age, median 
12.0 months, mean 30.4 months) 
for HBoV3 on the basis of sequence 
alignment and phylogenetic analysis 
of PCR amplicons. No specimens 
were positive for HBoV4. The number 
of samples positive for HBoV1, -2, 
and -3 in children <5 years old was 
124/131 (94.7%), 4/5 (80%), and 
4/5 (80%), respectively. Additional 
respiratory viruses were co-detected 
in 120/141 (85.1%) HBoV-positive 
patients (Table). An unanticipated 
fi nding was that real-time PCR only 
detected 1/5 positive sample for 
HBoV2 (viral load 4.87 × 109 copies/
mL) and 2/5 positive samples for 
HBoV3 (viral load 2.59 × 104 and 
4.1 × 102 copies/mL). In contrast, we 
detected viral loads of 8.35 × 104 to 
1.28 × 109 copies/mL in 5 randomly 
selected HBoV-1–positive samples.
The clinical diagnoses of 
patients providing HBoV-positive 
samples included pneumonia (63.1%), 
bronchitis (14.9%), bronchopneumo-
nia (12.8%), and acute asthmatic 
bronchopneumonia (9.2%). No 
clinically signifi cant differences were 
found between the signs and symptoms 
of patients with HBoV1, -2, and -3 
(cough, sputum production, fever, 
runny nose, wheezing, and diarrhea). 
For patients positive for HBoV3, the 
major diagnoses were pneumonia 
(2/5), bronchopneumonia (2/5), and 
acute asthmatic bronchopneumonia 
(1/5). Main signs and symptoms 
included cough (5/5), wheezing (4/5), 
sputum production (3/5), fever (3/5), 
runny nose (1/5), and diarrhea (1/5). 
For patients positive for HBoV2, 
the diagnoses were pneumonia (4/5) 
and bronchopneumonia (1/5), and 
main signs and symptoms included 
cough (5/5), sputum production (4/5), 
wheezing (3/5), fever (3/5), and runny 
nose (2/5) (Table).
HBoV2 and HBoV3 were detected 
sporadically during the study. HBoV3 
was detected in samples collected in 
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